Cell therapy

Tumour microenvironment
#Cell and gene therapy #Cell therapy #Interview #Oncology #T cell receptor (TCR)

Unlocking T-cell receptor therapy for cancer

Keir Loiacono, CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals. The first is… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell therapy #FDA #Kyverna Therapeutics #Regenerative Medicine Advanced Therapy

Kyverna receives advanced therapy designation for KYV-101

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutic’s CAR-T candidate KYV-101 for refractory stiff-person syndrome (SPS). KYV-101 is an autologous, fully human CD19 CAR-T cell product candidate for use in B cell-driven autoimmune diseases. The RMAT designation was based on… Read More

#News #Regulatory

Natural killer cells
#Cell therapy #Imperial College London #Interview #Natural killer cells #NK:IO #Oncology

Natural born killers: University spinout turns NK cell therapy into business

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR:  Cancer… Read More

#Cancer Research #Exclusive Content #Opinion #Start-up Zone

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Lupus #Paediatrics #Universitätsklinikum Erlangen

Successful off-label use of CAR-T therapy in a child with lupus

In June 2023, a patient at Universitätsklinikum Erlangen in Germany became the first child with lupus to receive CAR-T therapy. The treatment was the last resort to slow down systemic lupus erythematosus (SLE), which is a serious autoimmune disease that was attacking the patient’s body and… Read More

#Editor's Choice #News

MHRA
#Cell therapy #Clinical trials #Liver disease #Macrophages #MHRA #Resolution Therapeutics

Green light for engineered macrophage cell therapy study 

Resolution Therapeutics has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001 for patients with decompensated liver cirrhosis.   EMERALD is an open-label, Phase I/II study which will investigate the safety and… Read More

#News

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW's Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting around… Read More

#Exclusive Content #Trends & Analysis

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

New DDW Highlights podcast: 24 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been another busy week in the world of cell therapy, with the first… Read More

#News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

This week in drug discovery (17-21 June) 

News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer. It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of… Read More

#News

CAR-T for large B-cell lymphoma
#Allogene Therapeutics #allogeneic cell therapies #Cell therapy #Lymphoma #Oncology #Phase II trial

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More

#Cancer Research #News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Neurology

First use of CAR-T therapy in patient with stiff-person syndrome

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The therapy was given as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies. Read More

#News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Trophy
#CAR-T #Cell therapy #Harvard Medical School #Nobel Prize

Prize honours pioneers in CAR-T cell therapy

The 2024 Warren Alpert Foundation Prize has been awarded to four scientists whose discoveries led to the creation of chimeric antigen receptor (CAR)-T cells. The award recipients are: Renier Brentjens, Katherine Anne Gioia Endowed Chair of Medicine and Deputy Director of Roswell Park Comprehensive Cancer Center… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

New DDW Highlights podcast: 17 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With a lead story on the restoration of congenital hearing loss following gene therapy,… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

This week in drug discovery (10-14 June) 

News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation… Read More

#News